Efgartigimod Being Considered as Generalized MG Therapy for Europe

Efgartigimod Being Considered as Generalized MG Therapy for Europe

304145

Efgartigimod Being Considered as Generalized MG Therapy for Europe

The European Medicines Agency (EMA) has agreed to review Argenx’s application requesting the approval of its lead candidate, efgartigimod (ARGX-113), to treat people with generalized myasthenia gravis (gMG). A regulatory decision is expected by mid-2022. “gMG is a severe, chronic and debilitating disease that can be unpredictable and greatly impact a person’s quality of life,” Tim Van Hauwermeiren, Argenx’s CEO, said in a press release. “The EMA’s validation is an exciting step closer to our…

You must be logged in to read/download the full post.